NATCO PHARMA has announced its results for the quarter ended December 2019. Here is a detailed performance review of the same:
No. of Mths Qtr. Ending | 3 Dec-18* | 3 Sep-19* | 3 Dec-19* | QoQ Change | YoY Change | |
---|---|---|---|---|---|---|
Net Sales | Rs m | 5,567 | 4,857 | 4,822 | -0.7% | -13.4% |
Other income | Rs m | 233 | 332 | 308 | -7.2% | 32.2% |
Turnover | Rs m | 5,800 | 5,189 | 5,130 | -1.1% | -11.6% |
Expenses | Rs m | 3,483 | 3,514 | 3,535 | 0.6% | 1.5% |
Gross profit | Rs m | 2,084 | 1,343 | 1,287 | -4.2% | -38.2% |
Depreciation | Rs m | 207 | 219 | 254 | 16.0% | 22.7% |
Interest | Rs m | 63 | 62 | 53 | -14.5% | -15.9% |
Profit before tax | Rs m | 2,047 | 1,394 | 1,288 | -7.6% | -37.1% |
Tax | Rs m | 454 | 217 | 244 | 12.4% | -46.3% |
Profit after tax | Rs m | 1,593 | 1,177 | 1,044 | -11.3% | -34.5% |
Gross profit margin | % | 37.4 | 27.7 | 26.7 | ||
Effective tax rate | % | 22.2 | 15.6 | 18.9 | ||
Net profit margin | % | 27.5 | 22.7 | 20.4 |
To see how NATCO PHARMA has performed over the last eight quarters,please visit here.
FREE Event: How to Profit from the Massive Upcoming Revival in Smallcaps
Over the last one year,NATCO PHARMA share price has moved up from Rs 594.4 to Rs 669.8, registering a Gain of Rs 75.4 or around 12.7%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,198.8 (down 1.5%). Over the last one year it has moved up from 13,433.0 to 14,198.8, a gain of 766 points (up 5.7%).
Overall, the S&P BSE SENSEX is up 14.4% over the year.
At the current price of Rs 669.8, the price to earnings (P/E) ratio of NATCO PHARMA stands at 22.9 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.6 times.
For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More
| |
Equitymaster requests your view! Post a comment on "NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!